Southampton hospital study offers volunteers up to £3,700 - Here's what for

·3-min read
Professor Robert Read, Director of the NIHR Southampton Biomedical Research Centre, and sponsored by ILiAD Biotechnologies
Professor Robert Read, Director of the NIHR Southampton Biomedical Research Centre, and sponsored by ILiAD Biotechnologies

A HUMAN study for whooping cough has been launched in Southampton to test a new vaccine.

Volunteers are set to trial a new way to prevent whooping cough in a study led by University Hospital Southampton.

The hospital is appealing for people to sign up to take part.

It comes after a sharp increase in the number of cases in recent years from 6,216 in the years 2005-2011, to 25,891 between 2012-2018.

Healthy volunteers aged 18-50 who are recruited on the trial will be compensated up to £3,775 to take part in the study.

It will involve several visits to University Hospital Southampton and a 16-night stay at a hotel.

READ MORE: Southampton father-daughter duo offer advice to parents on mental health stigma

Known as a human challenge trial, the study will involve a nasal spray of the new vaccine, or a placebo.

An atomiser, which is similar to a nasal spray, will be used to deliver either the vaccine or a placebo into the nose of the participant.

After two to four months participants will then be deliberately infected with the bacteria that causes whooping cough, to see if they are protected.

This will be done in the controlled environment of the research clinic.

After this they will then stay at the study hotel for 16 nights.

READ MORE: Southampton event aims to 'break down barriers' surrounding mental health

Before they leave, they will be given a course of antibiotics to clear the bacteria from their nose.

The results of this study, CHAMPION-1, will help researchers find out if the BPZE1 vaccine can protect people from being infected with the disease-causing bacteria. It is what is known as a ‘challenge’ study

The research is led by Professor Robert Read, Director of the NIHR Southampton Biomedical Research Centre, and sponsored by ILiAD Biotechnologies.

It is being delivered by the NIHR Southampton Clinical Research Facility based in University Hospital Southampton Foundation NHS Trust.

Professor Read says: “Despite the dramatic decline in whooping cough during the 20th century, there has been a sharp increase in cases in recent decades.

"There is an important need for new and more effective vaccines. We are inviting people in the Southampton area to become part of this journey to best protect people against this life-threatening bacteria.”

A vaccine for whooping cough, or pertussis, is currently offered in the UK to all babies, and was first introduced 17 years ago.

However, it does not offer lifelong protection, cannot stop upper airway infections and does not prevent people from spreading it.

Whooping cough can cause persistent coughing and breathing difficulties for up to three months.

If you are interested in finding out more about taking part in this research visit

A message from the Editor

Thank you for reading this article - we appreciate your support in reading the Daily Echo.

Subscribing to the Echo means you have unrestricted access to the latest news, features and Saints coverage - all with an advertising-light website.

You will also have full access to Saintsplus, your new home for Southampton FC tactical analysis, features and much, much more.

Don't take my word for it - subscribe here to see for yourself.

Follow the latest breaking news in the Southampton area by joining our Facebook group - Southampton News - Breaking News and Incidents

Follow the latest court and crime news on our dedicated Facebook group - Hampshire Court and Crime News

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting